Promoted Content
Promoted Content

Find Oncology Drugs in Phase III Clinical Development in CHINA

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Selinexor,Dexamethasone,Bortezomib

            Therapeutic Area: Oncology Product Name: XPOVIO

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Karyopharm Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 03, 2020

            Details:

            XPOVIO® (selinexor, ATG-010) is a first-in-class and only-in-class oral selective inhibitor of nuclear export, developed by Antengene and Karyopharm Therapeutics Inc.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sintilimab,Bevacizumab

            Therapeutic Area: Oncology Product Name: Tyvyt

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 23, 2020

            Details:

            TYVYT® (sintilimab injection) in combination with BYVASDA® (bevacizumab biosimilar injection) demonstrated significantly improved overall survival and Independent Radiographic Review Committee progression-free survival versus sorafenib.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab,Pemetrexed,Carboplatin

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 21, 2020

            Details:

            The results showed sugemalimab plus chemotherapy as first-line treatment for advanced non-small cell lung cancer showed clinically meaningful benefit in PFS with a well-tolerated safety profile compared to chemotherapy across PD-L1 expression levels and histologies.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tislelizumab

            Therapeutic Area: Oncology Product Name: BGB-A317

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 17, 2020

            Details:

            The RATIONALE 303 trial is the third Phase 3 trial of tislelizumab in NSCLC that has achieved a positive outcome at interim analysis, and more importantly, marks the first global pivotal trial with a positive outcome in the tislelizumab clinical program.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): APL-1202

            Therapeutic Area: Oncology Product Name: APL-1202

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            The single oral drug therapy of APL-1202 has the potential to replace intravesical chemotherapy and thereby avoiding the pain and adverse reactions associated with catheterization. If proven, it should become a new choice to prevent cancer recurrence.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sintilimab,Bevacizumab

            Therapeutic Area: Oncology Product Name: Tyvyt

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 05, 2020

            Details:

            The seven studies of TYVYT® (sintilimab injection) to be presented on ESMO ASIA include one Proffered Paper Oral Presentation (a Phase 3 study) and six e-posters, covering indications including lung cancer, liver cancer, gastric cancer, and esophageal cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: EQRx

            Deal Size: $1,300.0 million Upfront Cash: $150.0 million

            Deal Type: Partnership October 27, 2020

            Details:

            Agreement provides a pathway to bring CStone's sugemalimab and CS1003 to global patient communities by partnering with a company with an innovative business model and unique ability to commercialize these two assets competitively against established treatments.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Pfizer Inc

            Deal Size: $480.0 million Upfront Cash: Undisclosed

            Deal Type: Collaboration September 30, 2020

            Details:

            This collaboration provides financing to support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including lung, gastric and esophageal cancers, among others.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Toripalimab,Gemcitabine

            Therapeutic Area: Oncology Product Name: JS001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 29, 2020

            Details:

            The results of the study showed that Toripalimab in combination with Gemcitabine/Cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma significantly extended the progression-free survival than Gemcitabine/Cisplatin.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sintilimab,Bevacizumab

            Therapeutic Area: Oncology Product Name: Tyvyt

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 28, 2020

            Details:

            The ORIENT-32 trial evaluati